| 臺大學術典藏 |
2022-06-27T07:00:03Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; CHONG-JEN YU; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:35Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; JIH-HSIANG LEE; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-07-13T06:04:33Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; LEE JIH-HSIANG; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-04-23T05:56:30Z |
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
|
Oxnard G.R.;Chih-Hsin Yang;Yu H.;Kim S.-W.;Saka H.;Horn L.;Goto K.;Ohe Y.;Mann H.;Thress K.S.;Frigault M.M.;Vishwanathan K.;Ghiorghiu D.;Ramalingam S.S.;Ahn M.-J.; Oxnard G.R.; CHIH-HSIN YANG; Yu H.; Kim S.-W.; Saka H.; Horn L.; Goto K.; Ohe Y.; Mann H.; Thress K.S.; Frigault M.M.; Vishwanathan K.; Ghiorghiu D.; Ramalingam S.S.; Ahn M.-J. |
| 臺大學術典藏 |
2020-08-13T06:33:33Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Yang J.C.-H.; Thress K.S.; Huang D.D.-R.; Bai Y.-Y.; Chang Y.-L.; Hsieh M.-S.; Su K.-Y.; Tsai T.-H.; Lee J.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; JIN-YUAN SHIH; Yu C.-J.; Lin C.-C.;Jin-Yuan Shih;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Hsieh M.-S.;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-08-13T06:33:33Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Yang J.C.-H.; Thress K.S.; Huang D.D.-R.; Bai Y.-Y.; Chang Y.-L.; Hsieh M.-S.; Su K.-Y.; Tsai T.-H.; Lee J.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; JIN-YUAN SHIH; Yu C.-J.; Lin C.-C.;Jin-Yuan Shih;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Hsieh M.-S.;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-08-12T02:50:40Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.;Shih J.-Y.;Yu C.-J.;Chao-Chi Ho;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Hsieh M.-S.;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; CHAO-CHI HO; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-08-12T02:50:40Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.;Shih J.-Y.;Yu C.-J.;Chao-Chi Ho;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Hsieh M.-S.;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; CHAO-CHI HO; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-07-21T06:46:19Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Yu C.-J.; CHAO-CHI HO; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H.; Lin C.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-07-21T06:25:17Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Yang J.C.-H.; Thress K.S.; Huang D.D.-R.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tzu-Hsiu Tsai;Su K.-Y.;Hsieh M.-S.;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; TZU-HSIU TSAI; Su K.-Y.; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y. |
| 臺大學術典藏 |
2020-07-21T06:25:17Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Yang J.C.-H.; Thress K.S.; Huang D.D.-R.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tzu-Hsiu Tsai;Su K.-Y.;Hsieh M.-S.;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; TZU-HSIU TSAI; Su K.-Y.; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y. |
| 臺大學術典藏 |
2020-06-30T08:09:56Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Kang-Yi Su;Hsieh M.-S.;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; KANG-YI SU; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-06-30T08:09:56Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Kang-Yi Su;Hsieh M.-S.;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; KANG-YI SU; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-26T09:26:46Z |
135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC
|
J?nne P.;Chih-Hsin Yang;Barrett C;Cantarini M;Paweletz C.P;Lawrance R;Alden R.S;Thress K.S;Oxnard G.R; Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; Barrett C; CHIH-HSIN YANG; Jänne P. |
| 臺大學術典藏 |
2020-05-26T09:26:46Z |
135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC
|
J?nne P.;Chih-Hsin Yang;Barrett C;Cantarini M;Paweletz C.P;Lawrance R;Alden R.S;Thress K.S;Oxnard G.R; Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; Barrett C; CHIH-HSIN YANG; Jänne P. |
| 臺大學術典藏 |
2020-05-26T09:26:44Z |
Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity
|
Box M; Johnström P; Varnäs K; Malmquist J; Thress K.S; Jänne P.A; Cross D.; Cross D.;J?nne P.A;Thress K.S;Malmquist J;Varn?s K;Johnstr?m P;Box M;Grist M;Hickey M;Jordan A;Pickup K;Cantarini M;Chih-Hsin Yang;Kim D.-W;Yang Z;Yates J.W.T;Ballard P; Ballard P; Yates J.W.T; Yang Z; Kim D.-W; CHIH-HSIN YANG; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M |
| 臺大學術典藏 |
2020-05-26T09:26:44Z |
Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity
|
Box M; Johnström P; Varnäs K; Malmquist J; Thress K.S; Jänne P.A; Cross D.; Cross D.;J?nne P.A;Thress K.S;Malmquist J;Varn?s K;Johnstr?m P;Box M;Grist M;Hickey M;Jordan A;Pickup K;Cantarini M;Chih-Hsin Yang;Kim D.-W;Yang Z;Yates J.W.T;Ballard P; Ballard P; Yates J.W.T; Yang Z; Kim D.-W; CHIH-HSIN YANG; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M |
| 臺大學術典藏 |
2020-05-26T09:26:44Z |
Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer
|
J?nne P.A.;Barrett J.C;Chih-Hsin Yang;Cantarini M;Paweletz C.P;Lawrance R;Alden R.S;Thress K.S;Oxnard G.R; Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; CHIH-HSIN YANG; Barrett J.C; Jänne P.A. |
| 臺大學術典藏 |
2020-05-26T09:26:44Z |
Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer
|
J?nne P.A.;Barrett J.C;Chih-Hsin Yang;Cantarini M;Paweletz C.P;Lawrance R;Alden R.S;Thress K.S;Oxnard G.R; Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; CHIH-HSIN YANG; Barrett J.C; Jänne P.A. |
| 臺大學術典藏 |
2020-05-26T09:26:37Z |
EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib
|
Shepherd F.A.;Cantarini M;Patel S;Dearden S;Weston S;Hodge R;Yu K;Thress K.S;J?nne P.A;Chih-Hsin Yang;Jenkins S; Jenkins S; Chih-Hsin CHIH-HSIN YANG; Jänne P.A; Thress K.S; Yu K; Hodge R; Weston S; Dearden S; Patel S; Cantarini M; Shepherd F.A. |
| 臺大學術典藏 |
2020-05-26T09:26:37Z |
EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib
|
Shepherd F.A.;Cantarini M;Patel S;Dearden S;Weston S;Hodge R;Yu K;Thress K.S;J?nne P.A;Chih-Hsin Yang;Jenkins S; Jenkins S; Chih-Hsin CHIH-HSIN YANG; Jänne P.A; Thress K.S; Yu K; Hodge R; Weston S; Dearden S; Patel S; Cantarini M; Shepherd F.A. |
| 臺大學術典藏 |
2020-05-26T09:26:35Z |
Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial
|
Thress K.S;Jacobs V;Angell H.K;Chih-Hsin Yang;Sequist L.V;Blackhall F;Su W.-C;Schuler M;Wolf J;Gold K.A;Cantarini M;Barrett J.C;J?nne P.A.; Thress K.S; Jacobs V; Angell H.K; CHIH-HSIN YANG; Sequist L.V; Blackhall F; Su W.-C; Schuler M; Wolf J; Gold K.A; Cantarini M; Barrett J.C; Jänne P.A. |
| 臺大學術典藏 |
2020-05-26T09:26:35Z |
Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial
|
Thress K.S;Jacobs V;Angell H.K;Chih-Hsin Yang;Sequist L.V;Blackhall F;Su W.-C;Schuler M;Wolf J;Gold K.A;Cantarini M;Barrett J.C;J?nne P.A.; Thress K.S; Jacobs V; Angell H.K; CHIH-HSIN YANG; Sequist L.V; Blackhall F; Su W.-C; Schuler M; Wolf J; Gold K.A; Cantarini M; Barrett J.C; Jänne P.A. |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): Overall survival and biomarker analyses
|
Soria J.-C.;Thress K.S;Haddad V;Rukazenkov Y;Shi X;Ponce S;Atagi S;Lu Y;Chih-Hsin Yang;Wang J;Ahn M.-J;Yang J.-J;Nakagawa K;Wu Y.-L;Kim S.-W;Mok T.S.K; Mok T.S.K; Kim S.-W; Wu Y.-L; Nakagawa K; Yang J.-J; Ahn M.-J; Wang J; CHIH-HSIN YANG; Lu Y; Atagi S; Ponce S; Shi X; Rukazenkov Y; Haddad V; Thress K.S; Soria J.-C. |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): Overall survival and biomarker analyses
|
Soria J.-C.;Thress K.S;Haddad V;Rukazenkov Y;Shi X;Ponce S;Atagi S;Lu Y;Chih-Hsin Yang;Wang J;Ahn M.-J;Yang J.-J;Nakagawa K;Wu Y.-L;Kim S.-W;Mok T.S.K; Mok T.S.K; Kim S.-W; Wu Y.-L; Nakagawa K; Yang J.-J; Ahn M.-J; Wang J; CHIH-HSIN YANG; Lu Y; Atagi S; Ponce S; Shi X; Rukazenkov Y; Haddad V; Thress K.S; Soria J.-C. |
| 臺大學術典藏 |
2020-05-26T09:26:31Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Chih-Hsin Yang;Thress K.S;Huang D.D.-R;Bai Y.-Y;Chang Y.-L;Hsieh M.-S;Su K.-Y;Tsai T.-H;Lee J.-H;Liao W.-Y;Ho C.-C;Yu C.-J;Shih J.-Y;Lin C.-C; Lin C.-C; Shih J.-Y; Yu C.-J; Ho C.-C; Liao W.-Y; Lee J.-H; Tsai T.-H; Su K.-Y; Hsieh M.-S; Chang Y.-L; Bai Y.-Y; Huang D.D.-R; Thress K.S; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:31Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Chih-Hsin Yang;Thress K.S;Huang D.D.-R;Bai Y.-Y;Chang Y.-L;Hsieh M.-S;Su K.-Y;Tsai T.-H;Lee J.-H;Liao W.-Y;Ho C.-C;Yu C.-J;Shih J.-Y;Lin C.-C; Lin C.-C; Shih J.-Y; Yu C.-J; Ho C.-C; Liao W.-Y; Lee J.-H; Tsai T.-H; Su K.-Y; Hsieh M.-S; Chang Y.-L; Bai Y.-Y; Huang D.D.-R; Thress K.S; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:30Z |
Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer
|
Ramalingam S.S; CHIH-HSIN YANG; Lee C.K; Kurata T; Kim D.-W; John T; Nogami N; Ohe Y; Mann H; Rukazenkov Y; Ghiorghiu S; Stetson D; Markovets A; Barrett J.C; Thress K.S; Jänne P.A.; J?nne P.A.;Thress K.S;Barrett J.C;Markovets A;Stetson D;Ghiorghiu S;Rukazenkov Y;Mann H;Ohe Y;Nogami N;John T;Kim D.-W;Kurata T;Lee C.K;Chih-Hsin Yang;Ramalingam S.S |
| 臺大學術典藏 |
2020-05-26T09:26:30Z |
Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer
|
Ramalingam S.S; CHIH-HSIN YANG; Lee C.K; Kurata T; Kim D.-W; John T; Nogami N; Ohe Y; Mann H; Rukazenkov Y; Ghiorghiu S; Stetson D; Markovets A; Barrett J.C; Thress K.S; Jänne P.A.; J?nne P.A.;Thress K.S;Barrett J.C;Markovets A;Stetson D;Ghiorghiu S;Rukazenkov Y;Mann H;Ohe Y;Nogami N;John T;Kim D.-W;Kurata T;Lee C.K;Chih-Hsin Yang;Ramalingam S.S |
| 臺大學術典藏 |
2020-05-25T07:35:13Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Chia-Chi Lin; Shih J.-Y; Yu C.-J; Ho C.-C; Liao W.-Y; Lee J.-H; Tsai T.-H; Su K.-Y; Hsieh M.-S; Chang Y.-L; Bai Y.-Y; Huang D.D.-R; Thress K.S; Yang J.C.-H. |
| 臺大學術典藏 |
2020-03-07T06:56:12Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; YIH-LEONG CHANG; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Hsieh M.-S.;Yih-Leong Chang;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-03-07T06:56:12Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; YIH-LEONG CHANG; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Hsieh M.-S.;Yih-Leong Chang;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-03-06T05:26:03Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; YIH-LEONG CHANG; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-03-05T08:04:01Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; MIN-SHU HSIEH; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Min-Shu Hsieh;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-03-05T08:04:01Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; MIN-SHU HSIEH; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Min-Shu Hsieh;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H. |
| 臺大學術典藏 |
2018 |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Yang J.C.-H.; Thress K.S.; Huang D.D.-R.; Bai Y.-Y.; Chang Y.-L.; Hsieh M.-S.; Su K.-Y.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Wei-Yu Liao;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Hsieh M.-S.;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; WEI-YU LIAO; Lee J.-H.; Tsai T.-H. |
| 臺大學術典藏 |
2018 |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Yang J.C.-H.; Thress K.S.; Huang D.D.-R.; Bai Y.-Y.; Chang Y.-L.; Hsieh M.-S.; Su K.-Y.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Wei-Yu Liao;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Hsieh M.-S.;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; WEI-YU LIAO; Lee J.-H.; Tsai T.-H. |
| 國立成功大學 |
2017 |
Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial
|
Thress, K.S.;Jacobs, V.;Angell, H.K.;Yang, J.C.-H.;Sequist, L.V.;Blackhall, F.;Su, W.-C.;Schuler, M.;Wolf, J.;Gold, K.A.;Cantarini, M.;Barrett, J.C.;J�nne, P.A. |
